Biología Molecular del VIH

Axis 1. Basic Research

L1: The use of nanoparticles as miRNA delivery agents

L2: Use of nanoparticles, mainly dendrimers, as microbicides against HIV-1, HSV and other sexually transmitted viruses

L3: Generation of organoids from human pluripotent stem cells: a platform for modeling infectious diseases. Nanotechnology-based therapies.

Axis 2. Clinical Research

L1: Design of immunomodulators and therapeutic vaccines based on dendritic cells against HIV and other sexually transmitted viruses

L2: Paediatric infection by HIV and other viruses

L3: Study of SARS-CoV2 infection in adult population and HIV/SARS-Co2 coinfection

Axis 3 BioBank

L1: Participation in clinical trials

L2: Private sample collections for specific projects and coordinated by the Director of the HGM HIV biobank, Dr. Muñoz-Fernández, the HGUGM has several cohorts of patients, such as the broncholitis cohort, neonatology, nephrology, rare diseases, respiratory diseases, sepsis, tuberculosis and the recent GesNEO cohort (pregnant women infected by SARS-CoV2 and their newborns) with biological samples stored in the BioBank